Trial · NCT01609556
Participant flow112
How many started, completed or left each group, period by period.
21 to 40 of 112
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | 9 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | 18 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | 7 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | 5 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | 5 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | 4 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | 9 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | 7 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | Received at Least 1 Dose of Study Drug | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | COMPLETED | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | COMPLETED | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | COMPLETED | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | COMPLETED | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | COMPLETED | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | COMPLETED | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | COMPLETED | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | 0 | |
| Dose Escalation: Maximum 101.3 Weeks | COMPLETED | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01609556/flow?page=2